Nektar Therapeutics
NKTRNektar Therapeutics is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances, which improves drug characteristics like retention and solubility. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, etc. The company developed the world's first inhalable non-injectable insulin, Exubera, which was awarded as the bronze award by Wall Street Journal for its technological breakthrough.
Drugs in Pipeline
14
Phase 3 Programs
5
Upcoming Catalysts
1
Next Catalyst
Aug 13, 2026
8dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
NKTR Earnings Report
EPS Est: $-1.94 | FQ end 2026-06 | Call: 2026-08-13 15:00:00
How NKTR's past catalysts played out
NKTR-102
Tumor
Rezpegaldesleukin
Moderate to Severe Atopic Dermatitis
NKTR-181 BID tablets
Low Back Pain
Treatment of Physician's Choice (TPC)
Locally Recurrent Breast Cancer
Eribulin
Metastasis
NKTR-181
Osteoarthritis of the Knee
NKTR-102 100 mg/m2
Tumor
NKTR-102 145 mg/m2
Malignant Solid Tumor
NKTR-255
Head and Neck Squamous Cell Carcinoma
irinotecan
Colorectal Cancer
Bempegaldesleukin
Urinary Bladder Neoplasm
NKTR-214
Unspecified Adult Solid Tumor, Protocol Specific
LY3471851
Systemic Lupus Erythematosus
NKTR-102 q14d
Tumor
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
NKTR-102 | Phase 3 | Tumor | - | - |
Rezpegaldesleukin | Phase 3 | Moderate to Severe Atopic Dermatitis | - | - |
NKTR-181 BID tablets | Phase 3 | Low Back Pain | - | - |
Treatment of Physician's Choice (TPC) | Phase 3 | Locally Recurrent Breast Cancer | - | - |
Eribulin | Phase 3 | Metastasis | - | - |
NKTR-181 | Phase 2 | Osteoarthritis of the Knee | - | - |
NKTR-102 100 mg/m2 | Phase 2 | Tumor | - | - |
NKTR-102 145 mg/m2 | Phase 2 | Malignant Solid Tumor | - | - |
NKTR-255 | Phase 2 | Head and Neck Squamous Cell Carcinoma | - | - |
irinotecan | Phase 2 | Colorectal Cancer | - | - |
Bempegaldesleukin | Phase 2 | Urinary Bladder Neoplasm | - | - |
NKTR-214 | Phase 2 | Unspecified Adult Solid Tumor, Protocol Specific | - | - |
LY3471851 | Phase 2 | Systemic Lupus Erythematosus | - | - |
NKTR-102 q14d | Phase 2 | Tumor | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Nektar Therapeutics's drug pipeline?→
CatalystAlert tracks 14 drug candidates in Nektar Therapeutics's (NKTR) pipeline across Phase 3, Phase 2. Its lead program is NKTR-102 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Nektar Therapeutics's next FDA catalyst?→
Nektar Therapeutics's (NKTR) next tracked catalyst is a Earnings expected August 13, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track NKTR biotech catalysts?→
Add NKTR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Nektar Therapeutics's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.